3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
18
Non-Muscle Invasive Bladder Neoplasms
12
Carcinoma, Transitional Cell
11
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Anus Neoplasms
5
Lung Neoplasms
4
Neoplasms
3
Carcinoma, Hepatocellular
3
Carcinoma
3
Urologic Neoplasms
2
Urologic Diseases
2
Urogenital Neoplasms
2
Urinary Bladder Diseases
2
Stomach Neoplasms
2
Neoplasms by Site
2
Colonic Neoplasms
2
Anal Canal Carcinoma
2
Uterine Cervical Neoplasms
1
Urogenital Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Pseudomyxoma Peritonei
1
Pancreatic Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms, Squamous Cell
1
Neoplasm Recurrence, Local
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Mycobacterium Infections
1
Interventions
pembrolizumab
4
Gemcitabine
4
padeliporfin
3
napabucasin
3
Pemetrexed
3
Paclitaxel
3
Drug Therapy
3
Cisplatin
3
Carboplatin
3
130-nm albumin-bound paclitaxel
3
ribociclib
2
palbociclib
2
Mitomycin
2
Gonadotropin-Releasing Hormone
2
Fluorouracil
2
Bevacizumab
2
Anastrozole
2
Albumin-Bound Paclitaxel
2
AZD9833
2
valrubicin
1
selinexor
1
pralsetinib
1
patritumab
1
palladium-bacteriopheophorbide
1
linifanib
1
ipatasertib
1
enfortumab vedotin
1
camrelizumab
1
atezolizumab
1
abemaciclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms by Site
×
Mitomycin
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled
NCT01200992
2017-08-24
EMBARC-RF
Bioniche Life Sciences Inc.
Phase 3
Terminated
84 enrolled
7 charts